Genentech Neuleze BLA Plans Nullified By Negative Trial Results
Executive Summary
Genentech has abandoned its plans to file a BLA for the nerve growth factor product Neuleze after a Phase III study of the agent in diabetic neuropathy "did not meet its objectives," Genentech said.